The FDA has approved an additional indication for human immune globulin IV (Rhophylac Rh0[D], CSL Behring) for the treatment of immune thrombo-cytopenic purpura (ITP). This product helps raise platelet counts in Rh0(D)-positive, non-splenectomized adults with chronic ITP.
This sterilized solution, obtained from pooled human plasma, was approved in 2004 for suppressing Rh isoimmuniza-tion in pregnancy and obstetric conditions and following an incompatible transfusion. It is used to prevent an immune response to Rh-positive blood in people with an Rh-negative blood type.
ITP is an autoimmune disease in which the immune system destroys the body’s platelets. Purple bruises on the skin (purpura) signify bleeding in small blood vessels under the skin, and small red splotches may be present on the skin. canadian pharmacy viagra
Rhophylac has also been used to prevent hemolytic disease of the newborn— which can affect an infant born as a result of an Rh-incompatible pregnancy—and to treat Rh-negative individuals in the event of an incompatible blood transfusion.